SARCOMA: Olaratumab — really a breakthrough for soft-tissue sarcomas?

    loading  Checking for direct PDF access through Ovid

Abstract

In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue sarcoma resulted in prolongation of progression-free survival by only 2.5 months, but an overall survival benefit of 11.8 months; the large disparity between these outcomes raises important questions. We discuss these results in relation to those of other trials, and the implications for sarcoma therapy.

Related Topics

    loading  Loading Related Articles